ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2016 American Transplant Congress

    3D-FLM (First, Last, Max): A Novel Summative Measure of Hepatocellular Carcinoma (HCC) Tumor Burden Predicts HCC Recurrence After Liver Transplantation (LT).

    E. Nordstrom,1 J. Dodge,2 J. Gralla,1 K. Campbell,1 C. Palmer,1 S. Biggins.1

    1Univ. Colorado, Aurora; 2UCSF, San Francisco.

    Risk of recurrent HCC post-LT depends on tumor aggressiveness, pre-LT HCC burden and treatment response while waiting for LT. Standard measures of pre-LT HCC burden…
  • 2016 American Transplant Congress

    Transplantation for Hepatocellularcarcinoma Is There a Tumor Size Limit?

    A. Daoud, L. Teeter, M. Ghobrial, E. Graviss, S. Mogawer, A. Sholkamy, M. Alshazly, H. Monsour, A. Gaber.

    Houston Methodist Hospital, Houston, TX; Cairo University Medical School, Cairo, Egypt; University of Arkansas for Medical Sciences, Little Rock, AR.

    Background:The advent of tumor size based criteria (Milan and UCSF) for transplantation of Hepatocellular carcinomas (HCC) has facilitated access of tumor patients to transplantation. Recent…
  • 2016 American Transplant Congress

    Use of Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma Does Not Increase Recurrence.

    A. Gupta, M. Ramsay, G. Saracino, T. Anthony, R. Goldstein, G. McKenna, N. Onaca, R. Ruiz, G. Klintmalm, P. Kim.

    Baylor University Medical Center, Dallas, TX.

    IntroductionAutotransfusion (AT) is rarely used in liver transplantation of hepatocellular carcinoma (HCC) patients due to the fear of disease transmission. Leukocyte depleting filters (LDF) can…
  • 2016 American Transplant Congress

    Intraoperative Blood Loss Is a Promoter of Early Tumor Recurrence in Liver Transplant Patients with High Risk Hepatocellular Carcinoma.

    A. Kornberg,1 U. Witt,1 J. Kornberg,2 H. Friess,1 K. Müller,3 K. Thrum.4

    1Surgery, Technical University, Munich, Germany; 2Anesthesiology, Ludwig-Maximilians-University, Munich, Germany; 3FSU, Jena, Germany; 4Pathology, Helios-Klinikum, Berlin, Germany.

    Background:Currently, there is an increasing body of evidence that risk of early hepatocellular carcinoma (HCC) relapse following liver transplantation (LT) may be promoted by mechanisms…
  • 2016 American Transplant Congress

    Assessing the Role of Everolimus in Reducing Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation for Patients within UCSF Criteria: Re-Inventing the Role of Mammalian Target of Rapamycine Inhibitors.

    L.-B. Jeng, A. Thorat, H.-R. Yang, T.-H. Chen, S.-C. Hsu.

    Organ Transplantation, China Medical University Hospital, Taichung, Taiwan.

    The antineoplastic effects of everolimus(EVR) in adjuvant to its conventional immunosuppressive role in post-transplant setting can theoretically reduce the tumor recurrence in hepatocellular carcinoma(HCC)patients undergoing…
  • 2016 American Transplant Congress

    Occult Multifocal Hepatocellular Carcinoma in Surgical Patients.

    D. Aufhauser Jr,1 E. Sadot,2 D. Murken,1 K. Eddinger,1 D. Goldberg,3 E. Furth,4 P. Abt,1 R. DeMatteo,2 M. Levine.1

    1Surgery, University of Pennsylvania, Philadelphia, PA; 2Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; 3Medicine, University of Pennsylvania, Philadelphia, PA; 4Pathology, University of Pennsylvania, Philadelphia, PA.

    Introduction: Resection of hepatocellular carcinoma (HCC) is associated with high rates of intrahepatic recurrence. However, it is unclear whether recurrence results from occult multifocal disease…
  • 2016 American Transplant Congress

    Comparative Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma (HCC-CCA) Undergoing Liver Transplantation: A Single Center Matched Cohort Analysis.

    K. Lunsford, M. Harlander-Locke, J. Gornbein, A. Zarrinpar, F. Kaldas, H. Yersiz, D. Farmer, R. Busuttil, V. Agopian.

    Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.

    Liver transplant (LT) is the gold standard for hepatocellular carcinoma (HCC) but is contraindicated in known HCC-CCA due to poor prognosis. We compared posttransplant oncologic…
  • 2016 American Transplant Congress

    Clinical Analysis of Patients with Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.

    D. Kim, G. Na, T. Hong, Y. You.

    Surgery, Seoul St. Mary's Hospital, Catholic University, Seoul, Korea.

    Purpose: For living-donor liver transplantation (LDLT), there has been a tendency to accept extended criteria in comparison with deceased-donor liver transplantation (DDLT). However, HCC recurrence…
  • 2016 American Transplant Congress

    Predictive Value of Preoperation Serum Gamma-Glutamyltranspeptidase for Hepatocellular Carcinoma Prognosis After Liver Transplantation.

    S. Fu, Q. Zhao, M. Chen, L. Wu, Q. Ren, F. Ji, Z. Guo, X. He.

    Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

    Objectives: The aims of this study were to evaluate the prognostic value of preoperative serum gamma-glutamyltranspeptidase (γ-GGT) in patients with hepatocellular carcinoma (HCC) underwent liver…
  • 2016 American Transplant Congress

    Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.

    M. Grąt,1 J. Stypułkowski,1 W. Patkowski,1 K. Wronka,1 M. Wasilewicz,2 K. Grąt,3 L. Masior,1 M. Krasnodębski,1 Z. Lewandowski,4 M. Krawczyk.1

    1Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland; 2Department of General, Transplant and Liver Surgery, Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland; 3Second Department of Clinical Radiology, Medical University of Warsaw, Warsaw, Poland; 4Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland.

    Milan criteria are considered as benchmark for selection of patients with hepatocellular cancer (HCC) for liver transplantation. The aim of this study was to evaluate…
  • « Previous Page
  • 1
  • …
  • 1192
  • 1193
  • 1194
  • 1195
  • 1196
  • …
  • 1683
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences